Clostridium difficile infection (CDI) has become the leading cause of healthcare associated infections in the United States and currently accounts for 15% to 20% of infectious diarrhea in the ...

PORT HUENEME, CA--(Marketwired - Jul 24, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today that a preclinical abstract on ...

What are the characteristics of C. difficile infection? Clostridium difficile is a Gram-positive bacterium that induces inflammation in the intestine via two toxins, namely TcdA and TcdB. A variety of ...

SAN DIEGO, April 2, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. announced today the presentation of information from insurance claims and survey databases highlighting the unmet need for ...

C. diff is a type of bacteria that can cause diarrhea, abdominal pain, and tenderness. It is commonly treated with antibiotics such as fidaxomicin (Dificid) and vancomycin (Firvanq). C. diff, short ...

SAN DIEGO, Sept. 15 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant ...

Dr. Dubberke presented the demographic and clinical characteristics of hospital inpatient CDI cases showing that the average CDI patient was 68 years old, more than half were female, and in total, 83% ...